×
News Home

What is Wall Street's Target Price for Navidea Biopharmaceuticals Inc (NAVB) Stock Tuesday?

Tuesday, February 23, 2021 02:21 PM | InvestorsObserver Analysts
What is Wall Street's Target Price for Navidea Biopharmaceuticals Inc (NAVB) Stock Tuesday?

Wall Street is positive on Navidea Biopharmaceuticals Inc (NAVB). On average, analysts give the stock a Strong Buy rating. The average price target is $7.5, which means analysts expect the stock to increase by 207.38% over the next twelve months.

That average ranking earns the stock an Analyst Rating of 78, which is better than 78% of stocks based on data compiled by InvestorsObserver.

Overall Score - 5
Wall Street analysts are rating NAVB a Strong Buy today. Find out what this means to you and get the rest of the rankings on NAVB!

Why are Analyst Ratings Important?

Analysts know the inner workings of the companies they follow better than anyone but the companies’ management. You can learn a lot about a company from studying the financial statements, but analysts ask questions on conference calls and understand the intricacies of each of the businesses they cover. Analysts understand how bad weather in one part of the world can disrupt supply chains, or disrupt shopping patterns. This lets traders make decisions before a quarterly report that could be worse than expected.

InvestorsObserver aggregates the ratings of all the analysts covering a given stock, takes the average of those ratings and then percentile ranks the averages. That provides a level of granularity that is significantly better than just the three levels provided by traditional buy/hold/sell ratings.

What's Happening With Navidea Biopharmaceuticals Inc Stock Today?

Navidea Biopharmaceuticals Inc (NAVB) stock is trading at $2.44 as of 2:01 PM on Tuesday, Feb 23, a decline of -$0.38, or -13.48% from the previous closing price of $2.82. The stock has traded between $2.40 and $2.74 so far today. Volume today is 355,599 compared to average volume of 468,275.

Click Here to get the full report on Navidea Biopharmaceuticals Inc (NAVB) Stock.

You May Also Like